Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
TALTORVIC
Synonyms :
ridaforolimus
Class :
Anti neoplastic agents
Brand Name :
TALTORVIC
Synonyms :
ridaforolimus
Class :
Anti neoplastic agents
Dosage forms and strengths Â
Indicated for advanced endometrial cancer
Phase 2 trials for this drug are presently underway
The intravenous administration dose is 12.5 mg every day for five days every alternate week
The oral administration dose is 40 mg a day for five days every three weeks
Not indicatedÂ
Refer adult dosingÂ
When abemaciclib is used together with ridaforolimus, this leads to enhanced concentration serum of abemaciclib
When acalabrutinib is used together with ridaforolimus, this leads to enhanced concentration serum of acalabrutinib
When acenocoumarol is used together with ridaforolimus, this leads to enhanced concentration serum of acenocoumarol
When alectinib is used together with ridaforolimus, this leads to enhanced concentration serum of alectinib
When alfentanil is used together with ridaforolimus, this leads to enhanced concentration serum of alfentanil
When alpelisib is used together with ridaforolimus, this leads to enhanced concentration serum of alpelisib
When alprazolam is used together with ridaforolimus, this leads to enhanced concentration serum of alprazolam
When aminophylline is used together with ridaforolimus, this leads to enhanced concentration serum of aminophylline
When amiodarone is used together with ridaforolimus, this leads to enhanced concentration serum of amiodarone
When astemizole is used together with ridaforolimus, this leads to enhanced concentration serum of astemizole
When axitinib is used together with ridaforolimus, this leads to enhanced concentration serum of axitinib
When bicalutamide is used together with ridaforolimus, this leads to enhanced concentration serum of bicalutamide
When bortezomib is used together with ridaforolimus, this leads to enhanced concentration serum of bortezomib
When bosutinib is used together with ridaforolimus, this leads to enhanced concentration serum of bosutinib
When brigatinib is used together with ridaforolimus, this leads to enhanced concentration serum of brigatinib
When bromocriptine is used together with ridaforolimus, this leads to enhanced concentration serum of bromocriptine
When budesonide is used together with ridaforolimus, this leads to enhanced concentration serum of budesonide
When busulfan is used together with ridaforolimus, this leads to enhanced concentration serum of busulfan
When cabazitaxel is used together with ridaforolimus, this leads to enhanced concentration serum of cabazitaxel
When cabergoline is used together with ridaforolimus, this leads to enhanced concentration serum of cabergoline
When ceritinib is used together with ridaforolimus, this leads to enhanced concentration serum of ceritinib
When cisapride is used together with ridaforolimus, this leads to enhanced concentration serum of cisapride
When clomipramine is used together with ridaforolimus, this leads to enhanced concentration serum of clomipramine
When clonidine is used together with ridaforolimus, this leads to enhanced concentration serum of clonidine
When clozapine is used together with ridaforolimus, this leads to enhanced concentration serum of clozapine
When cobimetinib is used together with ridaforolimus, this leads to enhanced concentration serum of cobimetinib
When conivaptan is used together with ridaforolimus, this leads to enhanced concentration serum of conivaptan
When copanlisib is used together with ridaforolimus, this leads to enhanced concentration serum of copanlisib
When corticotropin is used together with ridaforolimus, this leads to enhanced concentration serum of corticotropin
When cortisone acetate is used together with ridaforolimus, this leads to enhanced concentration serum of cortisone acetate
When crizotinib is used together with ridaforolimus, this leads to enhanced concentration serum of crizotinib
When cyclophosphamide is used together with ridaforolimus, this leads to enhanced concentration serum of cyclophosphamide
When dabrafenib is used together with ridaforolimus, this leads to enhanced concentration serum of dabrafenib
When dacomitinib is used together with ridaforolimus, this leads to enhanced concentration serum of dacomitinib
When dasatinib is used together with ridaforolimus, this leads to enhanced concentration serum of dasatinib
When deflazacort is used together with ridaforolimus, this leads to enhanced concentration serum of deflazacort
When deslanoside is used together with ridaforolimus, this leads to enhanced concentration serum of deslanoside
When dexamethasone is used together with ridaforolimus, this leads to enhanced concentration serum of dexamethasone
When dicoumarol is used together with ridaforolimus, this leads to enhanced concentration serum of dicoumarol
When digitoxin is used together with ridaforolimus, this leads to enhanced concentration serum of digitoxin
When digoxin is used together with ridaforolimus, this leads to enhanced concentration serum of digoxin
When dihydroergocornine is used together with ridaforolimus, this leads to enhanced concentration serum of dihydroergocornine
When dihydroergocristine is used together with ridaforolimus, this leads to enhanced concentration serum of dihydroergocristine
When dihydroergotamine is used together with ridaforolimus, this leads to enhanced concentration serum of dihydroergotamine
When docetaxel is used together with ridaforolimus, this leads to enhanced concentration serum of docetaxel
When dofetilide is used together with ridaforolimus, this leads to enhanced concentration serum of dofetilide
When doxorubicin is used together with ridaforolimus, this leads to enhanced concentration serum of doxorubicin
When dronabinol is used together with ridaforolimus, this leads to enhanced concentration serum of dronabinol
When dronedarone is used together with ridaforolimus, this leads to enhanced concentration serum of dronedarone
When enasidenib is used together with ridaforolimus, this leads to enhanced concentration serum of enasidenib
When enzalutamide is used together with ridaforolimus, this leads to enhanced concentration serum of enzalutamide
When erdafitinib is used together with ridaforolimus, this leads to enhanced concentration serum of erdafitinib
When ergoloid mesylate is used together with ridaforolimus, this leads to enhanced concentration serum of ergoloid mesylate
When ergometrine is used together with ridaforolimus, this leads to enhanced concentration serum of ergometrine
When ergotamine is used together with ridaforolimus, this leads to enhanced concentration serum of ergotamine
When erlotinib is used together with ridaforolimus, this leads to enhanced concentration serum of erlotinib
When estazolam is used together with ridaforolimus, this leads to enhanced concentration serum of estazolam
When etoposide is used together with ridaforolimus, this leads to enhanced concentration serum of etoposide
When everolimus is used together with ridaforolimus, this leads to enhanced concentration serum of everolimus
When finerenone is used together with ridaforolimus, this leads to enhanced concentration serum of finerenone
When fludrocortisone is used together with ridaforolimus, this leads to enhanced concentration serum of fludrocortisone
When fluindione is used together with ridaforolimus, this leads to enhanced concentration serum of fluindione
When flunisolide is used together with ridaforolimus, this leads to enhanced concentration serum of flunisolide
When fluprednisolone is used together with ridaforolimus, this leads to enhanced concentration serum of fluprednisolone
When fosphenytoin is used together with ridaforolimus, this leads to enhanced concentration serum of fosphenytoin
When hydrocortisone is used together with ridaforolimus, this leads to enhanced concentration serum of hydrocortisone
When ifosfamide is used together with ridaforolimus, this leads to enhanced concentration serum of ifosfamide
When ixazomib is used together with ridaforolimus, this leads to enhanced concentration serum of ixazomib
When lisuride is used together with ridaforolimus, this leads to enhanced concentration serum of lisuride
When meprednisone is used together with ridaforolimus, this leads to enhanced concentration serum of meprednisone
When metergoline is used together with ridaforolimus, this leads to enhanced concentration serum of metergoline
When methotrexate is used together with ridaforolimus, this leads to enhanced concentration serum of methotrexate
When methylprednisolone is used together with ridaforolimus, this leads to enhanced concentration serum of methylprednisolone
When methysergide is used together with ridaforolimus, this leads to enhanced concentration serum of methysergide
When midazolam is used together with ridaforolimus, this leads to enhanced concentration serum of midazolam
When midostaurin is used together with ridaforolimus, this leads to enhanced concentration serum of midostaurin
When neratinib is used together with ridaforolimus, this leads to enhanced concentration serum of neratinib
When nortriptyline is used together with ridaforolimus, this leads to enhanced concentration serum of nortriptyline
When ouabain is used together with ridaforolimus, this leads to enhanced concentration serum of ouabain
When pazopanib is used together with ridaforolimus, this leads to enhanced concentration serum of pazopanib
Actions and Spectrum:Â
Action:Â
Cell Cycle Arrest: Ridaforolimus interferes with the progression of the cell cycle by blocking the activity of mTOR. This leads to the arrest of cancer cells at specific points in the cell cycle, preventing their growth and replication.Â
Anti-proliferative Effects: By inhibiting mTOR, ridaforolimus inhibits the proliferation of cancer cells. This action helps in controlling the spread and growth of tumors.Â
Frequency not defined Â
Mouth soresÂ
Anemia Â
Hypophosphatemia Â
Diarrhea Â
Black Box Warning:Â Â
None
Contraindication/Caution:Â Â
Hypersensitivity: Ridaforolimus or any of its components should not be used by anyone who has previously shown hypersensitivity or severe allergic responses to them.Â
Pregnancy: Ridaforolimus can potentially harm an unborn baby. Therefore, it is generally contraindicated during pregnancy. Effective contraception should be used by women who are or may become pregnant both throughout therapy and for a while after the medicine is stopped.Â
Severe liver dysfunction: Ridaforolimus is metabolized by the liver, so individuals with severe liver impairment may require dosage adjustments or careful monitoring while taking this drug.Â
Severe kidney dysfunction: Patients with severe renal impairment may require dosage adjustments or careful monitoring while taking ridaforolimus.Â
Immunizations: Live vaccinations with ridaforolimus should be avoided during treatment due to the potential for decreased effectiveness and increased risk of infection.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: Ridaforolimus is a pharmacological agent classified as an mTOR inhibitor.Â
Pharmacodynamics:Â Â
mTOR Inhibition: Ridaforolimus selectively inhibits mTORC1, a crucial regulator of cell growth, protein synthesis, and metabolism.Â
Cellular Pathways: Ridaforolimus inhibits the growth of cancer cells by blocking mTORC1, interfering with the signaling pathways involved in the advancement of the cell cycle. Â
Pharmacokinetics:Â
AbsorptionÂ
The absolute bioavailability is 20% (IV).Â
DistributionÂ
Once absorbed, ridaforolimus is distributed throughout the body, with high concentrations found in the liver, lungs, and kidneys.Â
MetabolismÂ
Ridaforolimus is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system.Â
Excretion and EliminationÂ
The metabolites of ridaforolimus are excreted in the bile and feces, with a small amount eliminated in the urine.Â
Administration: Â
Route of Administration: Ridaforolimus is usually administered intravenously in a clinical setting, such as a hospital or infusion center. It’s given directly into the bloodstream through a vein.Â
Ridaforolimus is also given through the oral route.Â
Frequency of Administration: The frequency of ridaforolimus administration also varies depending on the treatment regimen prescribed by the healthcare provider.Â
Patient information leafletÂ
Generic Name: ridaforolimusÂ
Why do we use ridaforolimus? Â
Patients who have undergone previous treatment for advanced soft tissue sarcoma have been treated with ridaforolimus, as it helps in controlling the growth of cancer cells.Â
It has also been used in the treatment of metastatic or recurrent endometrial cancer, especially when alternative therapies have proven ineffective.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
